BridgeMD
New treatment option for Acute B-cell Lymphoblastic Leukemia
Official title Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
ClinicalTrials.gov ID: NCT06339775
What this study is testing
What is Blinatumomab?
Blinatumomab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for acute b-cell lymphoblastic leukemia.
Also referred to as donor lymphocyte infusion.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab. Anti-treatment was followed by DLI, and the second course was performed 1-2 months after DLI.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages up to 65
You may be able to join if
- Age ≤65 years old
- Stable vital signs
- No severe infection
- There was no grade II-IV graft-versus-host disease
- No organ failure
You likely can't join if
- Age \> 65 years old
- Unstable vital signs
- Complicated with severe infection
- Combined with grade Ⅱ-Ⅳ graft-versus-host disease
- Heart, liver, kidney and other organ failure
- Complicated with central nervous system leukemia
See the full eligibility criteria
- Age ≤65 years old
- Stable vital signs
- No severe infection
- There was no grade II-IV graft-versus-host disease
- No organ failure
- Age \> 65 years old
- Unstable vital signs
- Complicated with severe infection
- Combined with grade Ⅱ-Ⅳ graft-versus-host disease
- Heart, liver, kidney and other organ failure
- Complicated with central nervous system leukemia
- Allergies to medications in the treatment regimen
The study team makes the final eligibility decision.
Where it's taking place
- Zhenzhou, Henan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, up to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zhenzhou, Henan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.